| 1 |
Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 2 |
Fung J, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology 2018;68:462-72. [PMID: 29534307 DOI: 10.1002/hep.29874] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 3 |
Wong TCL, Fung JYY, Chok KSH, Cheung TT, Chan ACY, Dai WC, Ng KKC, Chan SC, Lo CM. Hepatitis B Vaccination in Patients Receiving Oral Antiviral Therapy Without Hepatitis B Immunoglobulin After Liver Transplant. Transplant Proc 2018;50:3681-8. [PMID: 30577255 DOI: 10.1016/j.transproceed.2018.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 4 |
Chaudhuri S, Symons JA, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Res 2018;155:76-88. [PMID: 29758235 DOI: 10.1016/j.antiviral.2018.05.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 20.6] [Reference Citation Analysis]
|
| 5 |
Bagg J, Roy K, Hopps L, Black I, Croser D, O'Halloran C, Ncube F. No longer 'written off' - times have changed for the BBV-infected dental professional. Br Dent J 2017;222:47-52. [PMID: 28084394 DOI: 10.1038/sj.bdj.2017.36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 6 |
Demirel A, Ozaras R. Future Drugs in the Treatment of HBV. Viral Hepatitis: Chronic Hepatitis B 2018. [DOI: 10.1007/978-3-319-93449-5_9] [Reference Citation Analysis]
|
| 7 |
Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 8 |
Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
